Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
PaperCitations, authors & open-access status
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 210 citations, 2023 year and closed oa status.
210
Citations
2023
Year
closed
OA Status